These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 18158731

  • 1. IFN-gamma is the only anti-rotavirus cytokine found after in vitro stimulation of memory CD4+ T cells from mice immunized with a chimeric VP6 protein.
    McNeal MM, Stone SC, Basu M, Clements JD, Choi AH, Ward RL.
    Viral Immunol; 2007 Dec; 20(4):571-84. PubMed ID: 18158731
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Mice develop effective but delayed protective immune responses when immunized as neonates either intranasally with nonliving VP6/LT(R192G) or orally with live rhesus rotavirus vaccine candidates.
    VanCott JL, Prada AE, McNeal MM, Stone SC, Basu M, Huffer B, Smiley KL, Shao M, Bean JA, Clements JD, Choi AH, Ward RL.
    J Virol; 2006 May; 80(10):4949-61. PubMed ID: 16641286
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Antibody-independent protection against rotavirus infection of mice stimulated by intranasal immunization with chimeric VP4 or VP6 protein.
    Choi AH, Basu M, McNeal MM, Clements JD, Ward RL.
    J Virol; 1999 Sep; 73(9):7574-81. PubMed ID: 10438847
    [Abstract] [Full Text] [Related]

  • 8. Targeting of rotavirus VP6 to DEC-205 induces protection against the infection in mice.
    Badillo-Godinez O, Gutierrez-Xicotencatl L, Plett-Torres T, Pedroza-Saavedra A, Gonzalez-Jaimes A, Chihu-Amparan L, Maldonado-Gama M, Espino-Solis G, Bonifaz LC, Esquivel-Guadarrama F.
    Vaccine; 2015 Aug 20; 33(35):4228-37. PubMed ID: 25850020
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Development of a Bacillus subtilis-based rotavirus vaccine.
    Lee S, Belitsky BR, Brinker JP, Kerstein KO, Brown DW, Clements JD, Keusch GT, Tzipori S, Sonenshein AL, Herrmann JE.
    Clin Vaccine Immunol; 2010 Nov 20; 17(11):1647-55. PubMed ID: 20810679
    [Abstract] [Full Text] [Related]

  • 14. Intradermal and intranasal immunizations with oligomeric middle layer rotavirus VP6 induce Th1, Th2 and Th17 T cell subsets and CD4+ T lymphocytes with cytotoxic potential.
    Heinimäki S, Malm M, Vesikari T, Blazevic V.
    Antiviral Res; 2018 Sep 20; 157():1-8. PubMed ID: 29935205
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Nasal immunization of mice with a rotavirus DNA vaccine that induces protective intestinal IgA antibodies.
    García-Díaz A, López-Andújar P, Rodríguez Díaz J, Montava R, Torres Barceló C, Ribes JM, Buesa J.
    Vaccine; 2004 Dec 09; 23(4):489-98. PubMed ID: 15530697
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparative immunogenicity in mice of rotavirus VP6 tubular structures and virus-like particles.
    Lappalainen S, Tamminen K, Vesikari T, Blazevic V.
    Hum Vaccin Immunother; 2013 Sep 09; 9(9):1991-2001. PubMed ID: 23777748
    [Abstract] [Full Text] [Related]

  • 20. VP6: A candidate rotavirus vaccine.
    Ward RL, McNeal MM.
    J Infect Dis; 2010 Sep 01; 202 Suppl():S101-7. PubMed ID: 20684688
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.